Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
san francisco blog main
san francisco top stories
10
×
national top stories
boston blog main
boston top stories
fda
new york blog main
new york top stories
raleigh-durham blog main
seattle blog main
seattle top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston
deals
gene editing
ipo
medical devices
national
startups
base editing
biofourmis
cancer
chronic kidney disease
What
therapeutics
10
×
million
startup
drug
new
bio
cancer
companies
crispr
editing
gene
immunotherapy
ipo
life
medicine
momentum
morning
nasdaq
raised
roundup
science
sciences
therapy
treat
week
adding
agency
aimmune
aims
allergy
allogene
analytics
approach
approval
approved
awarded
based
beam
benefit
bets
Language
unset
Current search:
therapeutics
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed